Aliskiren

Generic Name
Aliskiren
Brand Names
Rasilez, Tekturna, Tekturna Hct
Drug Type
Small Molecule
Chemical Formula
C30H53N3O6
CAS Number
173334-57-1
Unique Ingredient Identifier
502FWN4Q32
Background

Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.

Indication

Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.

Associated Conditions
Hypertension
Associated Therapies
-
Clinical Trials
Related News

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

Phase 1
Completed
Conditions
End Stage Renal Disease
Interventions
Drug: Aliskiren
First Posted Date
2012-04-02
Last Posted Date
2012-04-02
Lead Sponsor
Novartis
Target Recruit Count
12
Registration Number
NCT01568775
Locations
🇩🇪

Charité Universitätsmedizin, Berlin, Germany

Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Aliskiren
Drug: Hydrochlorothiazide
First Posted Date
2012-01-27
Last Posted Date
2020-03-17
Lead Sponsor
Centre Hospitalier Universitaire Vaudois
Target Recruit Count
24
Registration Number
NCT01519635
Locations
🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland

Shiga Microalbuminuria Reduction Trial-2

First Posted Date
2011-10-28
Last Posted Date
2018-02-19
Lead Sponsor
Shiga University
Target Recruit Count
237
Registration Number
NCT01461499
Locations
🇯🇵

Shiga University of Medical Science, Otsu, Shiga, Japan

Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany

First Posted Date
2011-10-19
Last Posted Date
2016-07-21
Lead Sponsor
Stiftung Institut fuer Herzinfarktforschung
Target Recruit Count
15337
Registration Number
NCT01454583

Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients

First Posted Date
2011-09-21
Last Posted Date
2017-05-01
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
10
Registration Number
NCT01437943
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension

Not Applicable
Terminated
Conditions
Hypertension
Abdominal Aortic Aneurysm
Interventions
Drug: Aliskiren
Drug: Amlodipine
First Posted Date
2011-08-29
Last Posted Date
2014-12-09
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
3
Registration Number
NCT01425242
Locations
🇳🇱

VU University Medical Center, Amsterdam, Netherlands

Aliskiren Effect on Aortic Plaque Progression

Phase 2
Terminated
Conditions
Atherosclerosis
Interventions
Drug: Aliskiren
Drug: Placebo
First Posted Date
2011-08-16
Last Posted Date
2017-05-11
Lead Sponsor
Ohio State University
Target Recruit Count
71
Registration Number
NCT01417104
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

First Posted Date
2011-08-04
Last Posted Date
2012-03-06
Lead Sponsor
Hospital Universitario Pedro Ernesto
Registration Number
NCT01409408
Locations
🇧🇷

Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil

Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients

Phase 4
Conditions
Hypertension
Dialysis
Interventions
Drug: Aliskiren
First Posted Date
2011-07-14
Last Posted Date
2012-07-10
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
350
Registration Number
NCT01394770
Locations
🇮🇹

Second Univesity of Naples, Naples, Italy

Aliskiren on Retinal Vasculature Treatment Study

Phase 3
Completed
Conditions
Arterial Hypertension
Interventions
Drug: Placebo
Drug: Aliskiren
First Posted Date
2011-03-18
Last Posted Date
2018-01-12
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Target Recruit Count
56
Registration Number
NCT01318395
Locations
🇩🇪

Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Nürnberg, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy